Incannex Healthcare Inc. Board of Directors

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research, development, manufacture, sale, and distribution of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that has completed Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate in Phase 2 clinical trial to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia.

Mr. Joel Bradley Latham

Mr. Joel Bradley Latham

President, CEO & Executive Director

Natalie May

Natalie May

Head of Clinical Operations

Mr. Lekhram Changoer M.Sc.

Mr. Lekhram Changoer M.Sc.

CTO & Member of Advisory Board

Mr. John Michailidis B.Sc., EMBA, M.A.I.C.D.

Mr. John Michailidis B.Sc., EMBA, M.A.I.C.D.

Chief Executive Officer of IncannexTM

Mr. Joseph Swan

Mr. Joseph Swan

CFO, Treasurer & Secretary

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.